A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins

Biomaterials

Volumn 32, Issue 4, 2011, Pages 1130-1138

  Ko, Hae Young ^a   Choi, Kyung Ju ^a   Lee, Chang Hyun ^a   Kim, Soonhag ^a  

^a CHA University   (South Korea)

Author keywords

Aptamer; Cancer targeting; Multimodal image; Nanoparticles; SMART

Indexed keywords

A549 CELLS; APTAMERS; CANCER BIOMARKERS; CANCER CELL LINES; CANCER IMAGING; CANCER-TARGETING; INTEGRINS; MOLECULAR IMAGING; MULTI-MODAL; MULTI-MODAL IMAGE; MULTI-MODAL NANOPARTICLES; NUCLEOLIN; SIGNAL INTENSITIES; SIGNAL SENSITIVITY; SMART; TENASCIN; WELL-DISPERSED;

BIOMARKERS; CELL CULTURE; MAGNETIC RESONANCE; MEDICAL IMAGING; NANOPARTICLES; TRANSMISSION ELECTRON MICROSCOPY;

PROBES;

ALPHA 5 INTEGRIN BETA 3; ALPHA5 INTEGRIN; BIOLOGICAL MARKER; GALLIUM 68; GALLIUM CHLORIDE; NANOPARTICLE; NUCLEOLIN; TENASCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DISEASE MARKER; FLUORESCENCE ANALYSIS; MOLECULAR IMAGING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOISOTOPE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; SIMULTANEOUSLY MULTIPLE APTAMER AND ARGININE GLYCINE ASPARTIC ACID PEPTIDE TARGETING CANCER PROBE; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; HUMANS; INTEGRIN ALPHAVBETA3; MATERIALS TESTING; MOLECULAR PROBES; NANOPARTICLES; NEOPLASMS; PHOSPHOPROTEINS; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; TENASCIN;

EID: 78649442434     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.034     Document Type: Article

References (35)

1. Weissleder R. Molecular imaging in cancer. Science 2006, 312:1168-1171.
2. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002, 99:12617-12621.
3. Cai W., Shin D.W., Chen K., Gheysens O., Cao Q., Wang S.X., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006, 6:669-676.
4. Lee K.Y., Kang H., Ryu S.H., Lee D.S., Lee J.H., Kim S. Bioimaging of nucleolin aptamer-containing 5-(N-benzylcarboxyamide)-2'-deoxyuridine more capable of specific binding to targets in cancer cells. J Biomed Biotechnol 2010, 168306.
5. Banerjee S.R., Pullambhatla M., Byun Y., Nimmagadda S., Green G., Fox J.J., et al. (68)Ga-Labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem 2010, 53:5333-5341.
6. Shah C., Miller T.W., Wyatt S.K., McKinley E.T., Olivares M.G., Sanchez V., et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009, 15:4712-4721.
7. Das M., Mishra D., Dhak P., Gupta S., Maiti T.K., Basak A., et al. Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging. Small 2009, 5:2883-2893.
8. Zaidi H. Is radionuclide transmission scanning obsolete for dual-modality PET/CT systems?. Eur J Nucl Med Mol Imaging 2007, 34:815-818.
9. Zaidi H., Mawlawi O., Orton C.G. Point/counterpoint. Simultaneous PET/MR will replace PET/CT as the molecular multimodality imaging platform of choice. Med Phys 2007, 34:1525-1528.
10. Kircher M.F., Mahmood U., King R.S., Weissleder R., Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003, 63:8122-8125.
11. Toma A., Otsuji E., Kuriu Y., Okamoto K., Ichikawa D., Hagiwara A., et al. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer 2005, 93:131-136.
12. De Santis R., Anastasi A.M., D'Alessio V., Pelliccia A., Albertoni C., Rosi A., et al. Novel antitenascin antibody with increased tumour localisation for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Br J Cancer 2003, 88:996-1003.
13. Chen X., Plasencia C., Hou Y., Neamati N. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 2005, 48:1098-1106.
14. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103:6315-6320.
15. Hwang do W., Ko H.Y., Lee J.H., Kang H., Ryu S.H., Song I.C., et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010, 51:98-105.
16. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
17. Flenniken M.L., Willits D.A., Harmsen A.L., Liepold L.O., Harmsen A.G., Young M.J., et al. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol 2006, 13:161-170.
18. Reubi J.C., Maecke H.R. Peptide-based probes for cancer imaging. J Nucl Med 2008, 49:1735-1738.
19. Tian X., Aruva M.R., Zhang K., Shanthly N., Cardi C.A., Thakur M.L., et al. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene-specific [64Cu]chelator-peptide nucleic acid-IGF1 analog radiohybridization probes. J Nucl Med 2007, 48:1699-1707.
20. Hausner S.H., DiCara D., Marik J., Marshall J.F., Sutcliffe J.L. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res 2007, 67:7833-7840.
21. Sivolapenko G.B., Douli V., Pectasides D., Skarlos D., Sirmalis G., Hussain R., et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody. Lancet 1995, 346:1662-1666.
22. Wurster S.E., Bida J.P., Her Y.F., Maher L.J. Characterization of anti-NF-kappaB RNA aptamer-binding specificity in vitro and in the yeast three-hybrid system. Nucleic Acids Res 2009, 37:6214-6224.
23. Li Y., Lee H.J., Corn R.M. Fabrication and characterization of RNA aptamer microarrays for the study of protein-aptamer interactions with SPR imaging. Nucleic Acids Res 2006, 34:6416-6424.
24. Lee J.F., Stovall G.M., Ellington A.D. Aptamer therapeutics advance. Curr Opin Chem Biol 2006, 10:282-289.
25. Patel D.J., Suri A.K., Jiang F., Jiang L., Fan P., Kumar R.A., et al. Structure, recognition and adaptive binding in RNA aptamer complexes. J Mol Biol 1997, 272:645-664.
26. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5:123-132.
27. Soundararajan S., Chen W., Spicer E.K., Courtenay-Luck N., Fernandes D.J. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res 2008, 68:2358-2365.
28. Cheng A.K., Su H., Wang Y.A., Yu H.Z. Aptamer-based detection of epithelial tumor marker mucin 1 with quantum dot-based fluorescence readout. Anal Chem 2009, 81:6130-6139.
29. Dassie J.P., Liu X.Y., Thomas G.S., Whitaker R.M., Thiel K.W., Stockdale K.R., et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009, 27:839-849.
30. Daniels D.A., Chen H., Hicke B.J., Swiderek K.M., Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 2003, 100:15416-15421.
31. Kang W.J., Chae J.R., Cho Y.L., Lee J.D., Kim S. Multiplex imaging of single tumor cells using quantum-dot-conjugated aptamers. Small 2009, 5:2519-2522.
32. Ko M.H., Kim S., Kang W.J., Lee J.H., Kang H., Moon S.H., et al. In vitro derby imaging of cancer biomarkers using quantum dots. Small 2009, 5:1207-1212.
33. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., et al. Tumor targeting by an aptamer. J Nucl Med 2006, 47:668-678.
34. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
35. Hwang do W., Ko H.Y., Kim S.K., Kim D., Lee D.S., Kim S. Development of a quadruple imaging modality by using nanoparticles. Chemistry 2009, 15:9387-9393.